U.S. market Closed. Opens in 11 hours 20 minutes

FHTX | Foghorn Therapeutics Inc. Stock Financials Income Statements Annual

(Stock Exchange: NASDAQ)
*Sign In to persist settings
Financial Year End2023-12-312022-12-312021-12-312020-12-312019-12-312018-12-31
Revenue34.16M19.23M1.32M430.00KN/AN/A
Cost of Revenue8.66M19.23K7.51M57.72M1.79MN/A
Gross Profit25.49M19.21M-6.20M-57.28M-1.79MN/A
Operating Expenses133.40M136.37M102.05M68.96M51.08M26.05M
Selling, General & Admin27.16M30.75M21.73M11.25M6.72M4.82M
Research & Development106.24M105.62M80.33M57.72M44.36M21.23M
Other Operating Expenses2.83M8.26M2.49MN/AN/AN/A
Operating Income-107.91M-117.14M-100.73M-68.53M-51.08M-26.05M
Other Expenses / Income13.71M8.26M-586.00K-269.00K-44.00K-30.00K
Before Tax Income-94.20M-108.88M-101.32M-68.80M-51.13M-26.34M
Income Tax Expenses4.23M-8.26K1.91M979.00K540.00K83.00K
Net Income-98.43M-108.87M-103.23M-69.78M-51.67M-26.34M
Interest ExpensesN/A-11.57M1.91M979.00K540.00K371.00K
Basic Shares Outstanding41.97M41.59M37.17M36.79M36.82M19.63M
Diluted Shares Outstanding41.97M41.59M37.17M36.79M36.82M19.63M
EBITDA-99.25M-117.14M-94.95M-66.20M-49.90M-25.56M
EBITDA Margin-290.57%-609.20%-7,198.94%-15,396.05%0.00%0.00%
EBIT-94.20M-120.45M-99.41M-67.82M-50.59M-25.88M
EBIT Margin-275.80%-626.43%-7,537.07%-15,772.33%0.00%0.00%
Financial Year End2023-12-312022-12-312021-12-312020-12-312019-12-312018-12-31
An error has occurred. This application may no longer respond until reloaded. Reload 🗙